Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners.
We are advancing a diverse pipeline of first-in-class or potentially best-in-class agents for hard-to-treat solid tumors and hematologic malignancies. This includes the industry’s leading SMARCA-targeted pipeline.
Our differentiation strategy is to design and optimize each of our small molecule therapeutics to possess specific properties that have the potential to benefit patients:
- PRT3789 (SMARCA2), we sought high selectivity over SMARCA4 to elicit synthetic lethality using a targeted protein degrader approach
- For PRT2527 (CDK9), we optimized for superior selectivity over previously developed CDK9i to improve tolerability
| Program | Potential Indications | Discovery | Phase 1 | Phase 2/3 | Upcoming Milestones |
|---|---|---|---|---|---|
| PR-01 | |||||
| Lead SMARCA2 Degrader (IV) |
SMARCA4-mutated NSCLC & other cancers | PRT3789 | Monotherapy Update – 2H 2025 First Chemo Combo Data – 2H 2025 | ||
| Oral SMARCA2 Degrader |
SMARCA4-mutated NSCLC & other cancers | PRT7732 | First Interim Phase 1 Data – 2H 2025 | ||
| SMARCA2/4 Precision ADCs* |
Broad range of cancers (heme & solid tumors) | First Pre-clinical PoC Data Presented at ENA; Additional Data in 2025 | |||
| Oral KAT6A Degrader |
ER+ breast cancer & other solid tumors | Dev’t Candidate (DC) Selection in 1H 2025, IND 1H 2026 | |||
| Discovery Engine | Hard-to-treat cancers, “undruggable” targets, high unmet need | Additional Pipeline Updates Planned in 2025 | |||
| Precision ADCs* | Broad range of cancers (heme & solid tumors) | Additional Data in 2025 | |||
| PR-01 | Lead SMARCA2 Degrader (IV) PRT3789 | |
| SMARCA4-mutated NSCLC & other cancers | ||
Discovery Phase 1 Phase 2 | ||
| Upcoming Milestones: Monotherapy Update – 2H 2025 First Chemo Combo Data – 2H 2025 | ||
| Oral SMARCA2 Degrader PRT7732 | ||
| SMARCA4-mutated NSCLC & other cancers | ||
Discovery Phase 1 Phase 2 | ||
| Upcoming Milestones: First Interim Phase 1 Data – 2H 2025 | ||
| SMARCA2/4 Precision ADCs* | ||
| Broad range of cancers (heme & solid tumors) | ||
Discovery Phase 1 Phase 2 | ||
| Upcoming Milestones: First Pre-clinical PoC Data Presented at ENA; Additional Data in 2025 | ||
| Oral KAT6A Degrader | ||
| ER+ breast cancer & other solid tumors | ||
Discovery Phase 1 Phase 2 | ||
| Upcoming Milestones: Dev’t Candidate (DC) Selection in 1H 2025, IND 1H 2026 | ||
| Discovery Engine | ||
| Hard-to-treat cancers, “undruggable” targets, high unmet need | ||
Discovery Phase 1 Phase 2 | ||
| Upcoming Milestones: Additional Pipeline Updates Planned in 2025 | ||
| Precision ADCs* | ||
| Broad range of cancers (heme & solid tumors) | ||
Discovery Phase 1 Phase 2 | ||
| Upcoming Milestones: Additional Data in 2025 | ||
*First Precision ADC Program discovered and advanced in collaboration with